ML-powered bioprocess modeling platform for pharma and biotech
Novasign applies hybrid AI models to bioprocess development—combining machine learning with mechanistic domain knowledge to compress timelines for drug manufacturing. The tech stack (React, TypeScript, Next.js, Python, C#) is built for real-time, data-rich applications. Four of six active hires are senior-level and focused on sales and commercial execution, reflecting a shift from R&D toward go-to-market scaling and market entry.
Novasign is a Vienna-based biotech software company spun out of the University of Natural Resources and Life Science Vienna. The platform applies hybrid AI models to accelerate bioprocess development—specifically upstream and downstream operations, CHO cell culture, and chromatography workflows—for pharmaceutical and biosimilar manufacturers. The product targets reducing development time and time-to-market for new molecules and biosimilars. The company is actively scaling its commercial function, with recent hiring concentrated on sales and structured funnel management across new geographies.
Frontend: React, TypeScript, Next.js, Material-UI, React Query. Visualization: ECharts, Plotly, Highcharts. Backend: C#, Python. Real-time comms: SignalR, WebSockets. Documentation: Storybook.
Go-to-market strategy, market entry and partnerships, sales funnel development, and real-time data applications. Recent projects emphasize commercial KPI dashboards and structured sales processes for SaaS expansion.
Other companies in the same industry, closest in size